Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
for Hematologic Malignancies
12 locations incl. Birmingham
Sponsor: Sellas Life Sciences Group
Sex: All·Age: 12+
Code: NCT04588922·Phase 1, Phase 2·Recruiting